Upregulation of AcrEF in Quinolone Resistance Development in Escherichia coli When AcrAB-TolC Function Is Impaired

Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease
Chuan-Zhen ZhangHong-Xia Jiang

Abstract

We studied mechanisms of drug resistance development in Escherichia coli strains lacking efflux pump components. E. coli K12 deletion mutants were subjected to increasing concentrations of ciprofloxacin (CIP) to determine the frequency of target gene mutations. We generated a series of mutants that were selected based on their minimum inhibitory concentrations (MICs) to CIP, as well as their corresponding point mutations in target genes. The mutants displayed a number of target modifications and, in particular, gyrA mutations altering codons Ser83Leu, Asp87Gly, and Asp87His as well as a change in parC at 78 (substitution of Gly for Asp). All these mutations were related to drug resistance. When exposed to CIP, mutants lacking efflux pump genes acrA and acrB demonstrated a low level of resistance that was because of point mutations in the target genes. High-level resistance was achieved with a 100- to 500-fold increase in expression of efflux pump genes acrE and acrF that compensated for the loss of AcrA and AcrB, and thus resulted in an obvious increase of CIP MIC. We demonstrate that an intact AcrAB-TolC efflux pump is crucial to the development of bacterial resistance. Its activity is complemented by expression of the alterna...Continue Reading

References

Jun 1, 2000·Proceedings of the National Academy of Sciences of the United States of America·K A Datsenko, B L Wanner
Jun 20, 2000·Antimicrobial Agents and Chemotherapy·J L Martinez, F Baquero
Sep 22, 2001·Journal of Bacteriology·K Nishino, A Yamaguchi
Mar 5, 2003·The Journal of Antimicrobial Chemotherapy·Shirley YangE Lynn Zechiedrich
May 25, 2004·The Journal of Biological Chemistry·Elena B Tikhonova, Helen I Zgurskaya
Apr 26, 2005·International Journal of Antimicrobial Agents·Katie L HopkinsE John Threlfall
Apr 12, 2007·PloS One·Miguel ViveirosLeonard Amaral
Dec 2, 2008·Biochimica Et Biophysica Acta·Helen I ZgurskayaGanesh Krishnamoorthy
Mar 18, 2009·Biochimica Et Biophysica Acta·Rajeev Misra, Vassiliy N Bavro
Apr 4, 2009·Proceedings of the National Academy of Sciences of the United States of America·Martyn F SymmonsVassilis Koronakis
Aug 6, 2013·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Sunita PaltansingAlexandra T Bernards
Feb 22, 2014·The Journal of Biological Chemistry·Naoki KobayashiSatoshi Murakami
Oct 20, 2015·Journal of the American Chemical Society·Jehangir CamaUlrich F Keyser

❮ Previous
Next ❯

Citations

Jan 17, 2020·Pharmacotherapy·Sara AlosaimyMichael J Rybak
Nov 20, 2020·Chemical Reviews·Philip A KlenoticEdward W Yu

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Software Mentioned

BLAST

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.